奈伐庫單抗
化合物
奈伐庫單抗（INN：Nesvacumab），或譯奈伐蘇單抗、耐斯伐庫單抗，是一種實驗性單株抗體，最初設計用於治療癌症。它的靶標是血管生成素2。[1][2]截至2017年5月，該藥物正處於治療糖尿病性黃斑水腫的II期臨床試驗中。[3][4]該藥物由再生元製藥公司開發。
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 血管生成素2 |
| 臨床資料 | |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 1296818-77-3 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6440H9966N1722O2008S38 |
| 摩爾質量 | 144,860.89 g·mol−1 |
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab （頁面存檔備份，存於網際網路檔案館）, American Medical Association.
- ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. October 2019, 28 (10): 861–869. PMID 31513439. doi:10.1080/13543784.2019.1667333.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov